Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.44 |
| ▸ | ABAT | P80404 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ALPI | P09923 | 1/20 | 0.43 |
| ▸ | ALPG | P10696 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.43 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3874121 | 0.82 | FFAR1 (0.57) | ALDH5A1ABATKDM4EALDH1A1GAA | |
| SCHEMBL3871935 | 0.82 | FFAR1 (0.57) | ALDH5A1ABATKDM4EALDH1A1GAA | |
| SCHEMBL11088941 | 0.81 | ALDH1A1 (0.53) | NPC1KDM4EALDH1A1GAATDP1 | |
| SCHEMBL13084164 | 0.81 | FFAR1 (0.49) | ALDH5A1ABATKDM4EALDH1A1BLM | |
| SCHEMBL27685565 | 0.78 | TDP1 (0.45) | KDM4EALDH1A1ALPGTDP1L3MBTL1 | |
| SCHEMBL27685528 | 0.78 | NPC1 (0.51) | NPC1RAB9AKDM4EALDH1A1GAA | |
| SCHEMBL27685597 | 0.78 | KMT2A (0.51) | NPC1RAB9AKDM4EALDH1A1GAA | |
| SCHEMBL18058892 | 0.77 | FFAR1 (0.49) | RAB9AKDM4EALDH1A1TDP1FFAR1 | |
| SCHEMBL27704467 | 0.76 | FFAR1 (0.55) | NPC1RAB9AKDM4EALDH1A1GAA | |
| SCHEMBL13715231 | 0.74 | CA12 (0.45) | KDM4EALDH1A1FFAR1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105797140-B | Stable formulations of hyaluronan degrading enzymes | 哈洛齐梅公司 | 2020-08-11 | — | — | CN | disclosed |
| US-9993529-B2 | Stable formulations of a hyaluronan-degrading enzyme | HALOZYME, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| EP-2720712-B1 | STABLE FORMULATIONS OF A HYALURONAN-DEGRADING ENZYME | HALOZYME INC (US) | 2016-03-02 | — | — | EP | disclosed |
| EP-2720712-A2 | STABLE FORMULATIONS OF A HYALURONAN-DEGRADING ENZYME | Halozyme, Inc. (US) | 2014-04-23 | — | — | EP | disclosed |
| EP-2720713-A2 | CONTINUOUS SUBCUTANEOUS INSULIN INFUSION METHODS WITH A HYALURONAN DEGRADING ENZYME | Halozyme, Inc. (US) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012174478-A9 | STABLE FORMULATIONS OF A HYALURONAN-DEGRADING ENZYME | HALOZYME, INC. (US) | 2013-05-30 | — | — | WO | disclosed |
| US-8431166-B2 | Composition comprising the extract of Anemarrhena asphodeloides Bunge or the compounds isolated from the same for preventing and treating lipid metabolism disorder | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2013-04-30 | — | — | US | disclosed |
| US-8431166-B2 | Composition comprising the extract of Anemarrhena asphodeloides Bunge or the compounds isolated from the same for preventing and treating lipid metabolism disorder | EWHA UNIVERSITY-INDUSTRY COLLABORATION FOUNDATION (KR) | 2013-04-30 | — | — | US | disclosed |
| US-20130022592-A1 | Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme | HALOZYME THERAPEUTICS, INC. | 2013-01-24 | — | — | US | disclosed |
| US-20130022588-A1 | Stable formulations of a hyaluronan-degrading enzyme related applications | HALOZYME THERAPEUTICS, INC. | 2013-01-24 | — | — | US | disclosed |
| US-20130011378-A1 | Stable formulations of a hyaluronan-degrading enzyme | HALOZYME THERAPEUTICS, INC. | 2013-01-10 | — | — | US | disclosed |
| WO-2012174480-A2 | CONTINUOUS SUBCUTANEOUS INSULIN INFUSION METHODS WITH A HYALURONAN DEGRADING ENZYME | HALOZYME, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2012174478-A2 | STABLE FORMULATIONS OF A HYALURONAN-DEGRADING ENZYME | HALOZYME, INC. (US) | 2012-12-20 | — | — | WO | disclosed |
| US-20120070515-A1 | Composition Comprising the Extract of Anemarrhena Asphodeloides Bunge or the Compounds Isolated from the Same for Preventing and Treating Lipid Metabolism Disorder | EWHA UNIVERSITY- INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-03-22 | — | — | US | disclosed |
| US-20120070515-A1 | Composition Comprising the Extract of Anemarrhena Asphodeloides Bunge or the Compounds Isolated from the Same for Preventing and Treating Lipid Metabolism Disorder | EWHA UNIVERSITY- INDUSTRY COLLABORATION FOUNDATION (KR) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130022588-A1 | Stable formulations of a hyaluronan-degrading enzyme related applications | IDE, MMP20, IDUA | NPC1 4491/4885PTPN1 2041/4885RAB9A 3219/4885 |
| US-20120070515-A1 | Composition Comprising the Extract of Anemarrhena Asphodeloides Bunge or the Compounds Isolated from the Same for Preventing and Treating Lipid Metabolism Disorder | FABP4, ACACB, LIPC | NPC1 327/4885PTPN1 1307/4885RAB9A 2255/4885 |
| US-20130011378-A1 | Stable formulations of a hyaluronan-degrading enzyme | IDE, IDUA, MMP20 | NPC1 4512/4885PTPN1 1926/4885RAB9A 3271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.